NTLA

NTLA R&D Expense Growth

-16.61%Fiscal year

Period ending:

NTLA FY R&D Growth (YoY)%
NTLA FY R&D Growth (YoY)209.25%-40.81%
2014-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year. Growth compares with the corresponding period one year earlier.

NTLA r&d expense growth history

Year-over-year research & development expense growth. The available annual fiscal periods series contains 12 observations from Dec 31, 2014 to Dec 31, 2025.

Intellia Therapeutics Inc R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
-16.6091%
7.1809%
3.593%
82.7529%
52.7891%
38.7361%
21.6552%
31.7353%
112.4592%
185.0492%
4.0037%
0%

Compare r&d expense growth

All NTLA financial metrics · NTLA stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.